Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.
Immunotherapy
Invasive mucinous adenocarcinoma
KRAS
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
09 Jun 2023
09 Jun 2023
Historique:
received:
12
04
2023
accepted:
20
05
2023
medline:
12
6
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Invasive mucinous adenocarcinoma (IMA) is a rare variant of adenocarcinoma with unique clinical, radiological, and pathological features, among which KRAS mutation is the most common. However, the differences in the efficacy of immunotherapy between KRAS-positive IMA and invasive non-mucinous adenocarcinoma (INMA) patients remain unclear. Patients with KRAS mutated adenocarcinomas receiving immunotherapy between June 2016 and December 2022 were enrolled. Based on mucin-producing status, the patients were placed into two subgroups: the IMA group and INMA group. Patients with IMA were further classified into two subtypes according to the presence of mucin patterns: pure IMA (≥ 90%) and mixed mucinous/nonmucinous adenocarcinoma (≥ 10% of each histological component). Kaplan-Meier Curves and log-rank tests were used to analyze survival. Cox regression analysis of PFS were used to analyze the independent factors associated with efficacy. Sixty-five advanced adenocarcinoma patients with KRAS mutations received immunotherapy, including 24 patients with IMA and 41 with INMA. The median progression-free survival (PFS) was 7.7 months, whereas the median overall survival (OS) was 24.0 months. Significant difference in PFS could be observed in IMA and INMA (3.5 months vs. 8.9 months; P = 0.047). Patients with pure IMA tended toward prolonger survival in contrast to mixed mucinous/nonmucinous adenocarcinoma in PFS (8.4 months vs. 2.3 months; P = 0.349). The multivariable analysis demonstrated that IMA was an independent risk factor for PFS. In KRAS mutated patients, IMA was associated with poorer PFS after immunotherapy compared with INMA.
Identifiants
pubmed: 37294384
doi: 10.1007/s12032-023-02059-w
pii: 10.1007/s12032-023-02059-w
doi:
Substances chimiques
KRAS protein, human
0
Mucins
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : the Medical Scientific Research Foundation of Zhejiang Province
ID : No.2022KY653
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Chang JC, Offin M, Falcon C, Brown D, Houck-Loomis BR, Meng F, Rudneva VA, Won HH, Amir S, Montecalvo J, Desmeules P, Kadota K, Adusumilli PS, Rusch VW, Teed S, Sabari JK, Benayed R, Nafa K, Borsu L, Li BT, Schram AM, Arcila ME, Travis WD, Ladanyi M, Drilon A, Rekhtman N. Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes. Clin Cancer Res. 2021;27(14):4066–76. https://doi.org/10.1158/1078-0432.CCR-21-0423 .
doi: 10.1158/1078-0432.CCR-21-0423
pubmed: 33947695
pmcid: 8282731
Gow CH, Hsieh MS, Liu YN, Lee YH, Shih JY. Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma. Cancers. 2021;13(16):4103. https://doi.org/10.3390/cancers13164103 .
doi: 10.3390/cancers13164103
pubmed: 34439256
pmcid: 8393953
Cai D, Li H, Wang R, Li Y, Pan Y, Hu H, Zhang Y, Gong R, Pan B, Sun Y, Chen H. Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. Onco Targets Ther. 2014;7:2127–32. https://doi.org/10.2147/OTT.S70984 .
doi: 10.2147/OTT.S70984
pubmed: 25429229
pmcid: 4242897
Yang SR, Chang JC, Leduc C, Tan KS, Dogan S, Benayed R, Borsu L, Offin M, Drilon A, Travis WD, Arcila ME, Ladanyi M, Rekhtman N. Invasive mucinous adenocarcinomas with spatially separate lung lesions: analysis of clonal relationship by comparative molecular profiling. J Thorac Oncol. 2021;16(7):1188–99. https://doi.org/10.1016/j.jtho.2021.03.023 .
doi: 10.1016/j.jtho.2021.03.023
pubmed: 33839364
pmcid: 8240964
Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Huang Q, Wang Y, Zheng J, Chen H. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. J Cancer Res Clin Oncol. 2016;142(8):1837–45. https://doi.org/10.1007/s00432-016-2201-9 .
doi: 10.1007/s00432-016-2201-9
pubmed: 27342421
Sun F, Wang P, Zheng Y, Jia W, Liu F, Xiao W, Bao J, Wang S, Lu K. Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. Oncol Lett. 2018;15:489–94. https://doi.org/10.3892/ol.2017.7312 .
doi: 10.3892/ol.2017.7312
pubmed: 29375717
Zhang S, Yu X, Huang Y, Nie P, Deng Y, Mao N, Li S, Zhu B, Wang L, Wang B, Wang X. Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers. BMC Pulm Med. 2022;22(1):460. https://doi.org/10.1186/s12890-022-02268-5 .
doi: 10.1186/s12890-022-02268-5
pubmed: 36461012
pmcid: 9719129
Wang T, Yang Y, Liu X, Deng J, Wu J, Hou L, Wu C, She Y, Sun X, Xie D, Chen C. Primary invasive mucinous adenocarcinoma of the lung: prognostic value of CT imaging features combined with clinical factors. Korean J Radiol. 2021;22(4):652. https://doi.org/10.3348/kjr.2020.0454 .
doi: 10.3348/kjr.2020.0454
pubmed: 33236544
Zhang X, Qiao W, Kang Z, Pan C, Chen Y, Li K, Shen W, Zhang L. CT features of stage IA invasive mucinous adenocarcinoma of the lung and establishment of a prediction model. IJGM. 2022;15:5455–63. https://doi.org/10.2147/IJGM.S368344 .
doi: 10.2147/IJGM.S368344
Yamakawa H, Takayanagi N, Ishiguro T, Kagiyama N, Shimizu Y, Sugita Y. A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma. Intern Med. 2013;52(24):2781–4. https://doi.org/10.2169/internalmedicine.52.0766 .
doi: 10.2169/internalmedicine.52.0766
pubmed: 24334585
Zhou D, Gulinuer W, Zhu N. Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: two case reports. Sci Prog. 2021;104(4):003685042110619. https://doi.org/10.1177/00368504211061971 .
doi: 10.1177/00368504211061971
Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer. 2016;102:82–8. https://doi.org/10.1016/j.lungcan.2016.11.004 .
doi: 10.1016/j.lungcan.2016.11.004
pubmed: 27987593
Chen Z, Li M, Ma K, Shang G, Liang J, Yin J, Luo J, Zhan C, Shi Y, Wang Q. Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. Cancer Med. 2020;9(2):517–29. https://doi.org/10.1002/cam4.2726 .
doi: 10.1002/cam4.2726
pubmed: 31769218
Moon SW, Choi SY, Moon MH. Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. J Thorac Dis. 2018;10(6):3595–608. https://doi.org/10.21037/jtd.2018.06.09 .
doi: 10.21037/jtd.2018.06.09
pubmed: 30069357
pmcid: 6051830
Gu Y, Zhu H, Deng J, Zhang J, Chen T, Lai S. Comparison of treatment strategies for resectable locally advanced primary mucinous adenocarcinoma of the lung. Cancer Med. 2023. https://doi.org/10.1002/cam4.5684 .
doi: 10.1002/cam4.5684
pubmed: 37351565
pmcid: 10278512
Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol. 2010;5(6):830–6. https://doi.org/10.1097/jto.0b013e3181d60ff5 .
doi: 10.1097/jto.0b013e3181d60ff5
pubmed: 20521350
Gianoncelli L, Spitaleri G, Passaro A, Fumagalli C, Del Signore E, Stati V, Catania CM, Guerini-Rocco E, Barberis M, Marinis DEF. Efficacy of anti-PD1/PD-L1 therapy (IO) in KRAS mutant non-small cell lung cancer patients: a retrospective analysis. Anticancer Res. 2020;40(1):427–33. https://doi.org/10.21873/anticanres.13970 .
doi: 10.21873/anticanres.13970
pubmed: 31892597
Veccia A, Dipasquale M, Kinspergher S, Monteverdi S, Girlando S, Barbareschi M, Caffo O. Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti-PD-1/PD-L1 therapy. Targ Oncol. 2023;18(1):129–38. https://doi.org/10.1007/s11523-022-00934-6 .
doi: 10.1007/s11523-022-00934-6
Knetki-Wróblewska M, Tabor S, Płużański A, Lewandowska Z, Tysarowski A, Pawlik H, Kowalski DM, Krzakowski M. Efficacy of immunotherapy in second-line treatment of KRAS-mutated patients with non-small-cell lung cancer—data from daily practice. Curr Oncol. 2022;30(1):462–75. https://doi.org/10.3390/curroncol30010037 .
doi: 10.3390/curroncol30010037
pubmed: 36661686
pmcid: 9858515
Peng L, Guo J, Kong L, Huang Y, Tang N, Zhang J, Wang M, He X, Li Z, Peng Y, Wang Z, Han X. Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: a real-world study in a Chinese population. Front Oncol. 2023;12:1070761. https://doi.org/10.3389/fonc.2022.1070761 .
doi: 10.3389/fonc.2022.1070761
pubmed: 36741723
pmcid: 9892536
Yoon HJ, Kang J, Lee HY, Lee MA, Hwang NY, Kim HK, Kim J. Recurrence dynamics after curative surgery in patients with invasive mucinous adenocarcinoma of the lung. Insights Imaging. 2022;13(1):64. https://doi.org/10.1186/s13244-022-01208-5 .
doi: 10.1186/s13244-022-01208-5
pubmed: 35380276
pmcid: 8982735
Boland JM, Maleszewski JJ, Wampfler JA, Voss JS, Kipp BR, Yang P, Yi ES. Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma—a clinicopathological and molecular genetic study with survival analysis. Hum Pathol. 2018;71:8–19. https://doi.org/10.1016/j.humpath.2017.08.002 .
doi: 10.1016/j.humpath.2017.08.002
pubmed: 28823574